The novelty of nutraceuticals

Food Technology

Volumn 59, Issue 10, 2005, Pages 63-66

  Ohr, Linda Milo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA-LACTALBUMIN; HEALTH CONCERNS; NUTRACEUTICALS; SLEEP COMPLAINTS;

BRAIN; FORESTRY; HEALTH CARE; HORMONES; LIPIDS; MARKETING; NUTRITION; PROTEINS; SEED;

DRUG PRODUCTS;

DRUGS; HEALTH; HORMONES; LIPIDS; PROTEINS; SEEDS; TREES;

BOVINAE; PINUS KORAIENSIS;

EID: 27844437542     PISSN: 00156639     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (7)

1. Cefalu, W.T., Bell-Farrow, A.D., Stegner, J., Wang, Z.Q., King, T., Morgan, T., and Terry, J.G. 1999. Effect of chromium picolinate on insulin sensitivity in vivo. J. Trace Elements Exp. Med. 12: 17-83.
2. Earnest, C.P., Jordan, A.N., Safir, M., Weaver, E., and Church, T.S. 2005. Cholesterol-lowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia. Am. J. Clin. Nutr. 81: 792-798.
3. Markus, C.R., Jonkman, L.M., Lammers, J.H.C.N. Deutz, N.E.P., Messer, M.H., and Rigtering, N. 2005. Evening intake of alpha-lactalbumin increases plasma tryptophan availability and improves morning alertness and brain measures of attention. Am. J. Clin. Nutr. 81: 1026-1033.
4. Mizuno, S., Matsuura, K., Gotou, T., Nishimura, S., Kajimoto, O., Yabune, M., Kajimoto, Y., and Yamamoto, N. 2005. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Brit. J. Nutr. 94(1): 84-91.
5. Orafti. 2005. Raftilose Synergyl shown to protect against colon cancer. Orafti Active Food Ingredients press release, April 14.
6. Palermo, C.M., Westlake, C.A., and Gasievicz, T.A. 2005. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry 44: 5041-5052.
7. Townsend, R.R., McFadden, C.B., Ford, V., and Cadée, J. A. 2004. A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. Am. J. Hypertension 17: 1056-1058.